AI in Pharma: Insilico's Breakthrough, Hospital Tech Dilemma, and DEA's Telehealth Extension
In this episode, we explore the transformative role of AI in the pharmaceutical industry, highlighting Insilico Medicine's Rentosertib, the first AI-discovered drug poised for Phase 3 clinical trials. With AI investments projected to reach $16.49 billion by 2034, industry leaders like Eli Lilly are at the forefront, collaborating with tech giants to revolutionize drug discovery. Despite AI's promise, experts caution about its limitations in human trials.
We also delve into the challenges hospitals face with new medical technology, likening it to a prisoner's dilemma. While robotic systems promise improved care, the costs and rapid tech advancements pose strategic dilemmas for healthcare providers.
Lastly, we discuss the DEA's extension of telemedicine prescribing flexibilities through 2026, a move applauded by telehealth advocates. This extension aims to ensure continued access to care while balancing human expertise with technology in healthcare practices.
Join Stan Berteloot, a French journalist and AI expert, as he navigates these intersections of technology and culture. As Head of Strategy and CTO at Nytro Marketing, Stan brings insights from his AI-driven content creation initiatives and his podcast, Back in America.
Stan Berteloot is a French journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.
As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.
Start your VoiceStream free trial today!
